Wednesday, September 30, 2009

Baxa Addresses Health-System Capital Shortage with New Programs for IntelliFlowRx™ and IntelliFill i.v.®

Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlow Rx Pharmacy Workflow Manager products. The Baxa IntelliSource™ program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate – without making capital investments, paying one-time setup fees or signing capital leases.

“Our goal was to make it easy for health systems to improve their pharmacy operations,” notes Greg Baldwin, Baxa CEO. “We feel that patient safety improvements shouldn’t take a back seat to this economy’s capital crunch. The IntelliSource pricing model makes it easy for health systems to install the latest pharmacy technology, eliminating the need for capital investment and providing manageable monthly fees for access.”

Thursday, September 24, 2009

Denver-based Cosmetic Acupuncture Expert Dr. Martha Lucas Conducts Intensive Seminar Sessions for Physicians in Istanbul

Martha Lucas, Ph.D., L.Ac., author of Vanity Calamity, recently taught Mei Zen™ Cosmetic Acupuncture to medical doctors in Istanbul. MDs in Turkey are trained in Acupuncture but don't necessarily have specialty training like that offered by Dr. Lucas.

A physician from Antalya, Turkey, had attended one of Dr. Lucas' cosmetic acupuncture seminars in the States last year and asked if she would teach Mei Zen™ Cosmetic Acupuncture in Turkey this year. According to Dr. Lucas, it is apparent women all over the world are searching for safe, natural, non-invasive cosmetic procedures of which Cosmetic Acupuncture is becoming one of the most popular.

Wednesday, September 23, 2009

The Colorado Cleantech Industry Association Announces Its Three-part "Smart Grid, Technology and Colorado" Series

The Colorado Cleantech Industry Association (CCIA) will be offering a three-part series this fall, “Smart Grid, Technology and Colorado.” The announcement is made by Christine Shapard, founding Executive Director of the CCIA who says, “We are pleased to announce the kickoff session in our series, Smart Grid: The Vision, on Wednesday, September 30, 7:30 a.m., at the Metro Denver Chamber of Commerce offices.”

The Series Kicks Off with Keynote Speaker Luke Clemente of General Electric (http://ge.ecomagination.com/smartgrid).

Registration is required, contact Shelly Curtiss at 303-623-2690 or Shelly@coloradocleantech.com – CCIA members attend free of charge; $50 for non-members. Subsequent sessions in the series are scheduled for Wednesday, October 28, and Tuesday, November 10. A breakfast buffet is provided at each of the sessions. Note space is limited and reservations are on a first-come, first-served basis. For more information, visit http://www.coloradocleantech.com/events.html

Tuesday, September 22, 2009

Chicago's Michael Rosen Praises Denver's Biotech Prowess

CHICAGO - In the world of biotech, the assumption is that the two poles of greatest and best activity center around San Francisco on the West Coast and Boston on the East Coast. This assumption is based on the historic role each city has played over the last 30+ years and the wealth of intellectual capital in the key research-based universities such as University of California - San Francisco and Stanford University in San Francisco and MIT and Harvard in Boston (just to name a few). It doesn't hurt that a large concentration of venture capital is located in each city/region.

True, a lot of good new medicines are coming out of each of the above regions, but good medicine, diagnostics and medical devices is not the purview of these regions only. Last week, while visiting Denver I participated in two different meetings which showed me that biotech is alive, abundant and well in Colorado and the Rocky Mountain region.

IntelliFlowRx™ Upgrades Expand Pharmacy Capabilities

Denver's Baxa Corporation announces the expansion of its IntelliFlowRx Workflow Manager system to include Preparation Modes, FormularyPlus™ and TPN processing capabilities. With more than 1,200 authorized users, IntelliFlowRx has prepared nearly three-quarters of a million safe patient doses.

The system streamlines the previously manual workflow for pharmacy doses. Through barcode drug verification, automatic dose calculation, image capture of dose creation and improving pharmacist checking activity, IntelliFlowRx ensures patients get the right dose of the right medication at the right time.

Sunday, September 20, 2009

Dr. Tom Cech's Rocky Mountain Life Science Investor Conference Keynote available at the COBioscience YouTube Channel



Over the last year, the State of Colorado has been anticipating Dr. Tom Cech's return to the University of Colorado Boulder and the implementation of the new Colorado Initiative for Molecular Biotechnology (CIMB). Dr. Cech provided the luncheon keynote presentation during the Rocky Mountain Life Science Investor Conference (Denver, Sept 17, 2009) and gave the audience a preview into his research and what the future holds. The CIMB will be opening its doors in December of 2011, and during Dr. Cech's presentation he discusses the collaboration and innovation that will generate from this unique project.

This is the first of four parts covering Dr. Cech's keynote at the Rocky Mountain Life Science Investor Conference Sept. 17, 2009, Ritz-Carlton, Denver.

Link to the COBioscience YouTube Video Channel

Friday, September 18, 2009

Biotech companies court venture capitalists: Medical Money

Business Reporter Andy Vuong and Photojournalist Ken Lyons took a close look at the inaugural Rocky Mountain Life Science Investor Conference - held in Denver, Sept. 17, at the Ritz-Carlton. Remarks included from Colorado Bioscience Association President & CEO John Collar:

"The event attracted 25 venture capital companies, two-thirds of which were from out of state, said John Collar, chief executive of the Colorado BioScience Association, co-sponsor of the conference.

The trade group, which has more than 400 members, initiated the conference to help improve access to capital for companies in the region at any stage of development, Collar said.

'Colorado is really seen as a developing hub of biosciences in the middle of the country as opposed to the established life-sciences industries in California and on the East Coast,' Collar said.

After their presentations, executives were provided with a private meeting room for discussions with potential investors. Now, it is up to the venture capitalists to choose which companies, if any, to support — a process that could take some time.

After speaking with some venture capitalists, Collar said he expected deals to close as a result of the conference.

He estimated that the companies, which included 15 from Colorado, were seeking a combined $150 million in funding."

Wednesday, September 16, 2009

MetroDenver: Life Science Investor Conference announces investors

"On Thursday, September 17, Denver will welcome 31 life science investors and business development professionals for the inaugural Rocky Mountain Life Science Investor Conference. This conference will showcase 30 of the region’s top life science companies to interested investors including business development professionals from large pharmaceutical, biotechnology, medical device and diagnostic companies.

'We are excited to welcome over 30 of the life science community’s most renowned investors to the inaugural Rocky Mountain Life Science Investor Conference,' said John Collar, President and CEO of the Colorado BioScience Association. 'This will allow Colorado and the Rocky Mountain region to offer an inside look into the innovation and talent that lies in this region, and we can’t wait to see the partnerships and connections made during this conference.'"

Denver Post Editorial: Middle ground on biologic meds

Colorado BioScience Association President & CEO John Collar quoted in Sunday Denver Post editorial:

"Colorado has emerged as a center for research and development of biologics. The industry directly employs more than 21,000 Coloradans, according to John Collar, the Colorado BioScience Association's president and chief executive. Many more are employed in support jobs.

From big players like Amgen to smaller labs and medical research departments at our larger universities, biologics mean promising careers and opportunities here. As many as 650 companies, big and small, have operations in Colorado. Collar says the state now ranks fifth in the nation in attracting venture capital for biologics."

Rocky Mountain Life Science Investor Conference: two Tucson bioscience firms picked to present to investors

"Two Tucson firms are among 30 presenting companies selected to showcase their innovations to investors and industry experts at the inaugural Rocky Mountain Life Science Investor Conference to be held Sept. 17 in Denver.

The two Tucson firms are High Throughput Genomics and Medipacs. . .

The meeting will also include speeches by Tom Cech, a Nobel Laureate in chemistry, and Roy Davis, president of corporate development for Johnson & Johnson, and panels discussions."

Friday, September 11, 2009

Colorado BioScience Association: 2009 Fall Focus Newsletter

A quarterly look at Colorado's Medical Device and Biotechnology Industries. Included in this issue:


The Rocky Mountain Investor Conference

The 2009 Summer Externship Program

Letter from John Collar, CBSA President & CEO

The Fitz Bulletin Board: 2009 BioSymposium on Pulmonary Disease

Link to a pdf of the new newsletter

Colorado's Dr. Tom Cech appears on CNBC Squawk Box

Wed. Jun. 10 2009 6:15 AM ET
Joe Kernen discussing the future of biomedical research, with Thomas Cech, 1989 Nobel Laureate in chemistry.

View the video at Medical Miracles - CNBC.com

Read "the rest of the story" about Joe Kernen at the Colorado Life Science Deal Flow blog

Make plans to attend the Sept 17 Rocky Mountain Life Science Investor Conference (RMLIC), where you'll get to hear Dr. Cech in person -- http://www.rmlic.com

Link to the latest RMLIC news release posted on the CNBC website

Thursday, September 10, 2009

Investors Announced: Rocky Mountain Life Science Investor Conference

On Thursday, September 17, Denver will welcome 31 life science investors and business development professionals for the inaugural Rocky Mountain Life Science Investor Conference. The conference will showcase 30 of the region’s top life science companies to interested investors including business development professionals from large pharmaceutical, biotechnology, medical device and diagnostic companies.

“We are excited to welcome over 30 of the life science community’s most renowned investors to the inaugural Rocky Mountain Life Science Investor Conference,” said John Collar, President and CEO of the Colorado BioScience Association. “This will allow Colorado and the Rocky Mountain region to offer an inside look into the innovation and talent that lies in this region, and we can’t wait to see the partnerships and connections made during this conference.”The 31 Investor firms and companies attending to date for the September 17 Conference include:
o Boulder Ventures, http://www.boulderventures.com
o Celgene, http://www.celgene.com
o Chart Life Scienceso Clovis Oncology
o Covidien, http://www.covidien.com
o Frazier Healthcare Ventures, http://www.frazierhealthcare.com
o Genentech, http://www.gene.com
o H.I.G. Ventures, http://www.higventures.com
o High Country Ventures, http://www.coloradofund1.com
o Hunt BioVentures, http://www.huntbioventures.com
o Johnson & Johnson, http://www.jjdevcorp.com
o Keld, LLC, http://www.keldllc.com
o KRG Capital Partners, http://www.krgcapital.com
o Lilly Ventures, http://www.lillyventures.com
o Mesa Verde Venture Partners, http://www.mesaverdevp.com
o Morgenthaler Ventures, http://www.morgenthaler.com
o NovaQuesto Novartis Venture Fund, http://www.venturefund.novartis.com
o Prairiegold Ventures, http://www.pgvp.com
o Puente Partnerso Red Script, http://www.jjdevcorp.com
o Rocky Mountain Venture Capital Association, http://www.rockymountainvca.com
o Sequel Ventures, http://www.sequelvc.com
o Skyline Ventures, http://www.skylineventures.com
o Sun Mountain Capital, http://www.sunmountaincapital.com
o Technology Partners, http://www.technologypartners.com
o Telegraph Hill Partners, http://www.thpartners.net
o vSpring Capital, http://www.vspring.com
o Yasuda Enterprise Development, http://www.yedvc.co.jp

Wednesday, September 09, 2009

ColoradoBiz TV: Andy Paliszewski of Siemens Energy at the CCIA Launch Event

Planet Profit Report

Andy Paliszewski of Siemens Energy talks about his company’s investment in renewable energy and the future of wind technology at the launch of the Colorado Cleantech Industry Association.

Monday, September 07, 2009

Colorado Cleantech Industry Association Selects Absolutely PR

"Colorado public relations consulting firm, Absolutely Public Relations (http://www.absolutelypr.com/), has been named the PR agency of record for the Colorado Cleantech Industry Association. The announcement was made by Maggie Chamberlin Holben, APR, owner/founder of Absolutely PR, who said the contract began earlier this year and two successful media relations campaigns are already yielding key media placements for the CCIA—both in traditional media outlets, as well as in the social media.

Sunday, September 06, 2009

University of Colorado to break ground on new biotech building that will house the Colorado Initiative in Molecular Biotechnology

"Colorado Gov. Bill Ritter, University of Colorado President Bruce Benson, Nobel Laureate and CU Distinguished Professor Tom Cech (pictured here), CU-Boulder Chancellor Philip DiStefano and members from the entire CU-Boulder community will gather Wednesday, Sept. 9, at 4:15 p.m. on the CU-Boulder East Campus to celebrate the groundbreaking of the Jennie Smoly Caruthers Biotechnology Building. . .

'This building will solidify the University of Colorado's position as a world leader in biotechnology and biochemistry,' said CU President Bruce D. Benson. 'It will provide leading-edge facilities to help foster collaboration among our faculty researchers and students from Boulder, Denver and the Anschutz Medical Campus. It will draw on the talents of scientists and engineers from several disciplines and create an incubator where innovation and discovery thrive.'

For the first time since its formation, the Colorado Initiative in Molecular Biotechnology's research team, a "dream team" of scientists and engineers spanning eight CU departments, will be housed in one location. The team received a boost this year when Cech, 1989 winner of the Nobel Prize in chemistry, rejoined CU's faculty in spring 2009 to head up the initiative."


Upcoming opportunity to hear Dr. Tom Cech: Dr. Cech will be delivering the keynote address at the Rocky Mountain Life Science Investor Conference, Sept. 17 at the Ritz-Carton, Denver. Link to register: http://www.rmlic.com/register.html

Absolutely PR adds social media offerings

"DENVER, CO: Absolutely PR added social media PR strategy and tactics to its product offerings. After having worked with current clients the Colorado BioScience Association (CBSA) and the Colorado Cleantech Industry Association (CCIA) on social media outreach, the agency now offers consulting on embracing tools including news feed blogs, SEO PR, podcasting, Wikipedia, Facebook, LinkedIn, Twitter, and video channels."


Saturday, September 05, 2009

"Ovarian Cancer, Awareness Now!" - 2nd Annual Ovarian Cancer March to the Colorado Capitol - Friday, Sept 4, 2009 Arrival at the Capitol Steps

video

"This is the second year my husband and I participated in support of our dear friend Elaine Rueb -- we also choose to support the COCA effort financially," Maggie Holben says. "The march, however, is about awareness. It was an awesome event again this year."

Link to the Colorado Ovarian Cancer Association website

Friday, September 04, 2009

Colorado is a stand out in the Clean Energy Economy




The August 28th Wall Street Journal mentioned Colorado in a quote from the Pew Environmental Group:

"'Oregon is one of the top three states in the country in terms of growing its clean-energy economy' along with Colorado and Tennessee, said Phyllis Cuttino, director of the Pew Environment Group's U.S. Global Warming campaign, a nonprofit that is part of the Pew Charitable Trusts."

The information comes from the June 2009 Pew report entitled "The Clean Energy Economy: Repowering Jobs, Businesses and Investments Across the Country." Colorado is singled among the "large and fast growing" category. Quoting from the report:

"Large and fast growing. Three states have large and fast-growing clean energy economies: Colorado, Oregon and Tennessee. In 2007, each of these states exceeded the national averages for both the number of jobs in the clean energy economy (15,106) and the average annual growth rate for those jobs (1.9 percent). These states are geographically dispersed, demonstrating that location is not the sole factor in the success and vitality of a state’s clean energy economy. Tennessee has had success developing jobs in the Conservation and Pollution Mitigation category, which includes recycling, waste treatment and water management; more than three quarters of the state’s jobs in the clean energy economy are in this category. Colorado has capitalized on its natural wind and sun resources to stimulate job growth in Clean Energy, while Oregon has become a leader in Energy Efficiency, with a quarter of its jobs in the clean energy economy in this category."

Tuesday, September 01, 2009

Colorado Life Science Deal Flow: The Best $200 You Can Spend on 9/17, Rocky Mountain Life Science Investor Conference

From CLSDF's Adam Rubenstein: "If you have not heard about the upcoming Rocky Mountain Life Science Investor Conference at the Ritz Carlton – Denver on 17 September, yet, you sure will get an earful about it here at CLSDF.

Today’s post particularly applies to those companies who have applied to present at the RMLSIC and were not selected as well as those entities who have not applied (perhaps you thought you were not ready to present yet?). Knowing that capital raising in our world is essentially, well…essential, the perspective of institutional life science investors is key in helping to highlight and address the critical “commercially relevant” questions that an early-stage entity must focus upon in order to efficiently leverage finite resources."